Compare GPMT & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | CLNN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.9M | 120.6M |
| IPO Year | 2017 | N/A |
| Metric | GPMT | CLNN |
|---|---|---|
| Price | $2.14 | $4.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 190.7K | 124.7K |
| Earning Date | 02-11-2026 | 03-23-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.12 | $82.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $2.28 |
| 52 Week High | $3.19 | $13.50 |
| Indicator | GPMT | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 33.70 |
| Support Level | $2.06 | $3.88 |
| Resistance Level | $2.25 | $4.50 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 4.55 | 9.68 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.